The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer
- 1 November 2000
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 86 (7) , 802-804
Abstract
Objectives To assess the validity of the prophylactic use of pirarubicin ([2′R]‐4‐O‐tetrahydropyranyl‐doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side‐effects.Keywords
This publication has 16 references indexed in Scilit:
- BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)Journal of Urology, 1999
- EFFECTIVENESS OF A SINGLE IMMEDIATE MITOMYCIN C INSTILLATION IN PATIENTS WITH LOW RISK SUPERFICIAL BLADDER CANCER: SHORT AND LONG-TERM FOLLOWUPJournal of Urology, 1999
- TRANSURETHRAL RESECTION WITH PERIOPERATIVE INSTILLATION OF INTERFERON-alpha OR EPIRUBICIN FOR THE PROPHYLAXIS OF RECURRENT PRIMARY SUPERFICIAL BLADDER CANCER: A PROSPECTIVE RANDOMIZED MULTICENTER STUDY-FINNBLADDER IIIJournal of Urology, 1999
- Absorption of Epirubicin Instilled Intravesically Immediately after Transurethral Resection of Superficial Bladder CancerUrologia Internationalis, 1998
- Single‐dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional‐cell bladder tumours: a prospective, randomized controlled studyBritish Journal of Urology, 1997
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of FollowupJournal of Urology, 1996
- Prophylactic chemotherapy with anthracyclines (Adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancerCancer Chemotherapy and Pharmacology, 1994
- Cooperative Study of Therapy of Superficial Bladder Cancer by Intravesical Instillation of PirarubicinAmerican Journal of Clinical Oncology, 1990
- Comparative investigation on use of (2 ″R)-4′-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumorsUrology, 1988